7:00 AM

 
Continental Breakfast
8:00AM   John Rennie, Editor in Chief, Scientific American

 

Jeffrey M. Leiden, M.D., Ph.D., President and Chief Operating Officer, Abbott Laboratories
Introduction of Dr. Jeffrey M. Drazen

8:15 AM

  

Jeffrey M. Drazen, M.D., Editor-in-Chief, New England Journal of Medicine, Distinguished Parker B. Francis Professor of Medicine, Harvard Medical School
From Shotguns to Rifles—Precise Targeting of Treatment

 

 

8:45 AM   Catherine M. Burzik, President, Applied Biosystems
Breakthrough Products to Drive the Realization of Targeted Medicine
  Michael E. Svinte, V.P., Information Based Medicine, IBM Healthcare and Life Sciences
Information Based Medicine: A New Era in Patient Care
  Jeffrey Trent, Ph.D., President & Scientific Director, The Translational Genomics Research Institute (TGen)
Targeting Existing Drugs to Genetic Signatures
 

John Graham, Principal, Ernst & Young
Economic Opportunities for Targeted Medicine

9:45 AM   Michael F. Press, M.D., Ph.D., Professor and Coordinator, Women's Cancer Research Program, University of Southern California and Steven A. Seelig, M.D., Ph.D., V.P. Research, Abbott Molecular Diagnostics
Lesson Learned From the Development of a Diagnostic to Predict Response to Herceptin

10:15 AM

   Coffee Break

 


10:45 AM

  

Nicholas C. Dracopoli, Ph.D., Vice President, Clinical Discovery Technologies, Bristol-Myers Squibb
Pharmacogenomic Applications in Drug Development

 

Stephen W. Fesik, Ph.D., Divisional Vice President, Cancer Research, Abbott Laboratories
Predicting the Cancers Likely to Respond to Bcl-2 Family Inhibitors From Preclinical Studies

 

Richard Hockett, M.D., Group Leader for Genomic Medicine, Eli Lilly and Company
Comprehensive Metabolic Enzyme and Transporter Gene Analysis

 

 

 

  

 
11:45 AM
  

Dennis A. Ausiello, M.D., Physician-in-Chief, Massachusetts General Hospital
Targeted Medicine: The Future is Now

 

Samuel Broder, M.D., Chief Medical Officer, Celera Genomics
Translating Personalized Medicine into Practice

  Michael P. O'Boyle, Chief Financial Officer, The Cleveland Clinic Foundation and Health System
What are the Financial Issues for Bringing Targeted Medicines to the Formulary?
  Arthur L. Caplan, Ph.D., Director, Center for Bioethics, University of Pennsylvania School of Medicine
Hit But Miss?
 
12:45 AM   Luncheon Keynote
Lawrence J. Lesko, Ph.D., Director, Office of Clinical Pharmacology and Biopharmaceutics, Food and Drug Administration
How is the FDA Enabling the Use of Pharmacogenomics in Drug Development and Product Labels of Approved Drugs?

1

   Introduction of Dr. Lawrence J. Lesko
Thomas J. White, Ph.D., Chief Scientific Officer, Celera Diagnostics
 

2

    
2:30 PM   Kathy Ordoñez, President, Celera Genomics and Celera Diagnostics
Converging Technologies for Targeted Medicine
    Joyce G. Schwartz, M.D., V.P. and Chief Laboratory Officer, Quest Diagnostics
Continuing the Progression to Customized Care
    Eric J. Topol, M.D., Provost and Chief Academic Officer, Cleveland Clinic Foundation
The Emerging "Smart-Medicine" Approach to Healthcare
    Felix W. Frueh, Ph.D., Associate Director for Genomics, FDA/CDER
FDA's Guidance Initiative on Drug/Test Combination Products
     

   
3:30 PM   Brian B. Spear, Ph.D., Director, Pharmacogenomics, Abbott Laboratories
Targeted Medicine: Scientific, Strategic and Commercial Opportunities
    Patrice M. Milos, Ph.D., Senior Director Pharmacogenomics, Translational Biomarkers and DNA Sequencing, Pfizer Global R&D
Can We Achieve Precision Medicine?
    Susan Hall, Ph.D., Director, Regulatory Affairs, GlaxoSmithKline
Managing Pipeline Attrition Through Targeted Approaches

4:30 PM

   John Rennie, with Q&A for all speakers from audience

5:00 PM

  

7:00 PM End of Symposium